1. Introduction

Cancer genomic discrimination refers to unfair treatment of a person because of genetic information indicating an increased risk of developing cancer, a hereditary cancer-predisposition variant, or a family history that suggests a genetic susceptibility to cancer.

For example, a person who carries a pathogenic variant in the BRCA1 or BRCA2 gene may have an increased risk of developing certain cancers. Such a person may face discrimination if an employer, insurer, or other institution treats them as though they already have cancer, despite their being healthy.

The law must balance several interests:

Individual autonomy and privacy: A person should generally control access to sensitive genetic information.

Equality and non-discrimination: Predictive genetic risk should not automatically become a basis for exclusion.

Public health and scientific progress: Genetic research and clinically useful testing should remain possible under appropriate safeguards.

Legitimate institutional interests: Employers and insurers may have lawful operational or underwriting interests, but these do not automatically override applicable anti-discrimination or privacy protections.

An important distinction is that genetic susceptibility is not the same as a cancer diagnosis. A genetic test may indicate increased probability, but it cannot establish with certainty that a person will develop cancer.

Genomic discrimination protections therefore concern not only discrimination against people who have cancer, but also discrimination against healthy people who may develop cancer in the future.

2. Meaning and scope of genomic discrimination

Cancer-related genomic discrimination can occur in several settings.

Not every adverse decision involving genetic information is automatically unlawful. The outcome depends on the jurisdiction, the type of information, the institution involved, the relevant statute, and the evidence of discrimination.

3. Legal framework in India

India does not have a single, comprehensive statute specifically prohibiting every form of cancer-related genetic discrimination. Protection instead arises from constitutional principles, privacy and data-protection law, disability law where applicable, insurance regulation, and general civil or consumer remedies.

A. Constitutional protection: Articles 14 and 21

Article 14 — Equality before the law

Article 14 prohibits arbitrary state action and requires legally relevant distinctions to be justified. If a public authority excludes an individual from employment, a public benefit, or a service solely because of an unproven assumption about their hereditary cancer risk, the decision may be challenged as arbitrary or discriminatory.

Article 21 — Life, personal liberty, privacy and dignity

Article 21 protects life and personal liberty. The constitutional right to privacy also protects informational privacy and personal autonomy. Genetic information is particularly sensitive because it may reveal not only information about the tested individual but also possible health risks affecting biological relatives.

A public authority's collection or use of genomic information must therefore be examined in light of legality, legitimate purpose, and proportionality.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 (DPDP Act) establishes a framework for processing digital personal data, including identifiable genomic test results stored digitally.

Its relevance includes lawful processing, applicable notice and consent requirements, security safeguards, and statutory rights and remedies as the relevant provisions come into force.

However, two qualifications matter:

The Act does not create a blanket, standalone prohibition on all cancer-genetic discrimination.

Its application depends on the provisions and rules in force at the relevant time, the type of processing, and any applicable statutory exemptions.

Genomic information held only in non-digital form may fall outside the Act's ordinary scope unless it is subsequently digitised. Other legal obligations may still apply.

C. Disability and employment law

A person who has cancer may qualify for protection under the Rights of Persons with Disabilities Act, 2016, depending on the applicable statutory criteria and circumstances. Cancer susceptibility alone does not automatically establish a disability under that Act.

Employment protections may also arise from constitutional requirements applicable to public employment, relevant service rules, disability law, and general legal principles. India does not have a direct equivalent of the United States' Genetic Information Nondiscrimination Act (GINA) that comprehensively prohibits employers from using genetic information.

D. Insurance regulation and consumer protection

An insurer's reliance on a broad genetic-risk exclusion may raise questions of contractual interpretation, fairness, regulatory compliance, and the evidentiary basis for the underwriting decision.

The legal analysis should distinguish between:

a hereditary predisposition without diagnosed disease;

a diagnosed cancer or other existing condition;

a claim made under a specific policy exclusion; and

a denial based on inaccurate, incomplete, or improperly obtained information.

A disputed insurance decision is not automatically unlawful merely because genetic information was involved. Its validity depends on the governing policy, applicable regulations, the evidence, and the relevant court decisions.

4. Important Indian case laws

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1 · Supreme Court of India

Facts and legal issue

A nine-judge Constitution Bench considered whether the right to privacy is protected as a fundamental right under the Indian Constitution.

Judgment

The Court unanimously recognised privacy as a constitutionally protected fundamental right, including as an aspect of Article 21. The judgment addressed informational privacy, personal autonomy, and the conditions under which privacy may lawfully be restricted.

Indian Kanoon+1

Application to cancer genomic discrimination

The decision provides a foundational constitutional basis for challenging unjustified collection, disclosure, or use of identifiable genetic information.

For example, a public authority that compels a healthy applicant to disclose hereditary cancer results without lawful authority or a proportionate justification may face a constitutional challenge.

The judgment does not, by itself, establish a specific right to compensation for every instance of genomic discrimination or automatically invalidate all private-sector insurance decisions.

Legal principle: Genetic information can engage informational privacy and autonomy, and any state intrusion must satisfy constitutional standards.

Case 2: United India Insurance Co. Ltd. v. Jay Prakash Tayal (2018)

Delhi High Court, judgment dated 26 February 2018; subsequent Supreme Court proceedings

Facts and legal issue

The litigation concerned an insurance policy exclusion relating to genetic disorders. The dispute raised questions about whether broadly worded exclusions could be used to deny health-insurance protection without an adequate evidentiary or legal basis.

Judgment and subsequent procedural history

The Delhi High Court criticised the broad exclusion of genetic disorders and discussed the relationship between health insurance, access to healthcare, equality, and genetic discrimination.

Importantly, the Supreme Court subsequently stayed the operation of the High Court judgment to the extent indicated in its order. The High Court's conclusions must therefore not be presented as an unqualified, presently operative nationwide rule.

2018 Supreme(SC) 2003

Application to cancer genomic discrimination

The case is relevant when an insurer relies on a broad exclusion that may encompass hereditary cancer susceptibility without clearly distinguishing genetic predisposition from an actual diagnosed disease.

A policyholder might argue that the exclusion is ambiguous, arbitrary, or inconsistent with applicable law. The insurer may respond that the policy expressly excludes the relevant condition and that its decision is contractually and legally justified.

The outcome depends on the policy wording, later judicial orders, applicable insurance regulations, and the facts of the claim.

Legal principle: Broad genetic-disorder exclusions raise significant questions of fairness and legal scrutiny, but the precise binding effect of the decision must be assessed in light of the subsequent stay.

Case 3: Maneka Gandhi v. Union of India (1978)

Citation: (1978) 1 SCC 248 · Supreme Court of India

Facts and legal issue

The case concerned the impounding of a passport and the requirements of fairness under Article 21.

Judgment

The Supreme Court established that a procedure affecting life or personal liberty must satisfy standards of fairness and non-arbitrariness. The judgment significantly influenced the interpretation of Article 21 and its relationship with Article 14.

Indian Kanoon+1

Application to genomic discrimination

Suppose a government employer excludes an otherwise qualified candidate because a genetic report predicts a possible future cancer risk. If the decision lacks a lawful basis, uses an unfair procedure, or rests on arbitrary assumptions, constitutional principles developed in Maneka Gandhi may support a challenge.

This is an application of the case's general constitutional principles, not a ruling specifically about genetic testing.

Legal principle: Decisions affecting legally protected interests must meet applicable standards of fairness and non-arbitrariness.

5. Important United States case laws

The United States provides a more explicit statutory framework for genetic discrimination, particularly through the Genetic Information Nondiscrimination Act of 2008 (GINA). These decisions are useful for comparative legal analysis but are not binding on Indian courts.

Case 4: Norman-Bloodsaw v. Lawrence Berkeley Laboratory (1998)

135 F.3d 1260 · United States Court of Appeals for the Ninth Circuit

Facts: Employees challenged undisclosed medical screening that included testing for sensitive conditions and traits, including sickle-cell trait. Their claims included privacy and discrimination-related allegations.

Judgment: The Ninth Circuit addressed the employees' claims concerning undisclosed testing and the applicable limitation-period questions. It held that factual disputes about when the employees knew or should have known about the testing prevented summary judgment on the relevant timeliness issue. The case was subsequently settled.

Every CRS Report

Relevance to cancer genomics: The case illustrates why the manner in which genetic information is obtained matters. Secret testing, inadequate disclosure, and the collection of sensitive information without appropriate justification can raise serious legal issues.

Limitation: This was not a decision under GINA, which was enacted later, and it did not establish a general statutory ban on all genetic testing.

Case 5: EEOC v. Burlington Northern Santa Fe Railway Co. (2002 settlement)

This matter concerned allegations that a railway employer secretly subjected employees seeking workers' compensation for carpal tunnel syndrome to genetic testing for a marker allegedly associated with the condition.

The dispute ended in a settlement involving $2.2 million and cessation of the challenged testing program, according to a Congressional Research Service historical account.

Every CRS Report

Relevance: The dispute demonstrates the dangers of obtaining genetic information in an employment context without employees' informed knowledge.

Limitation: It was a settlement, not a final judicial ruling establishing liability after trial. It should not be cited as binding case-law precedent on the merits.

Case 6: EEOC v. Founders Pavilion, Inc. (2013 settlement)

This employment-discrimination matter involved allegations that an employer improperly sought family medical history during employment-related medical examinations.

The case is relevant because family medical history can reveal potential hereditary cancer risk even when no genetic test has been performed.

The distinction matters under GINA: employers may not circumvent restrictions on genetic information by asking intrusive questions about relatives' medical conditions.

Legal significance: Employers must carefully limit medical inquiries and follow the applicable statutory exceptions. A settlement, however, should not be confused with a contested appellate judgment establishing a universal rule.

For the governing employment standard, the EEOC's official explanation of GINA is a stronger primary source.

U.S. Equal Employment Opportunity Commission+1

6. The Genetic Information Nondiscrimination Act of 2008 (GINA)

United States federal law · 42 U.S.C. § 2000ff et seq.

GINA is one of the clearest statutory models for protecting individuals against discrimination based on genetic information.

Two principal protections

Title II — Employment

Prohibits covered employers from discriminating against applicants and employees because of genetic information. It also generally restricts acquisition and disclosure of that information.

Title I — Health coverage

Restricts the use of genetic information by covered health plans and issuers in eligibility, premium, and underwriting decisions, subject to the applicable statutory framework.

Official sources:

Genome.gov+1

What counts as genetic information?

Under GINA, the definition generally includes:

An individual's genetic test results.

Genetic tests of family members.

Family medical history.

Requests for or receipt of genetic counselling or genetic services.

Certain genetic information obtained through research or assisted reproduction.

Thus, a person may be protected even if they have never undergone genetic testing. A family history of hereditary breast cancer can itself constitute genetic information for GINA purposes.

U.S. Equal Employment Opportunity Commission+1

What GINA does not cover

GINA has important limitations:

It does not generally prohibit discrimination by life, disability, or long-term-care insurers on the basis of genetic information.

It does not replace disability protections for a person who already has cancer.

Its employment provisions generally apply to covered employers with at least 15 employees.

It does not guarantee that every form of medical information will be treated as genetic information.

For someone who already has cancer, the Americans with Disabilities Act (ADA), applicable health laws, and other relevant protections may be more important than GINA alone.

U.S. Equal Employment Opportunity Commission+2

7. Distinguishing genetic susceptibility from diagnosed cancer

This distinction is central to genomic discrimination law.

A hereditary predisposition should not automatically be treated as proof of present incapacity, a current illness, or certainty of future disease.

However, where a person already has cancer, a claim based on the actual diagnosis must be analysed separately from a claim based on genetic predisposition.

8. Burden of proof and evidentiary issues

A person alleging cancer-genomic discrimination generally needs to establish the relevant legal elements under the law governing the dispute.

The evidence may include:

Proof of genetic information: A genetic test report, medical record, family-history questionnaire, or evidence that the decision-maker learned of genetic counselling.

Proof of adverse treatment: Rejection from employment, dismissal, an insurance denial, an adverse premium decision, or another legally relevant disadvantage.

Evidence of causation: Communications, internal policies, underwriting records, timing of the decision, or statements suggesting that genetic information influenced the outcome.

Evidence concerning justification: The applicable policy wording, statutory exceptions, documented decision criteria, and the actual medical or occupational requirements involved.

The burden of proof varies considerably between jurisdictions and causes of action. In the United States, GINA has specific statutory requirements; in India, a constitutional, contractual, consumer, privacy, or employment claim will have its own applicable rules.

Important: The mere fact that a person has a cancer-predisposition variant and subsequently experiences an adverse decision does not necessarily prove unlawful discrimination. Evidence connecting the decision to the genetic information is often critical.

9. Legal remedies and enforcement

Depending on the jurisdiction and the type of violation, possible remedies may include:

Reconsideration of a discriminatory employment or insurance decision.

Compensation or damages where legally available.

Injunctions against unlawful collection, use, or disclosure of genetic information.

Complaints to an appropriate regulator or equality body.

Consumer-dispute or contractual proceedings against an insurer.

Constitutional judicial review of unlawful or arbitrary state action.

Corrective measures, deletion or restriction of data processing where legally available.

In the United States, employment complaints under GINA are generally handled by the Equal Employment Opportunity Commission (EEOC). The EEOC identifies a usual filing deadline of 180 days, potentially extended to 300 days where qualifying state or local law applies. Different deadlines and procedures apply in other contexts.

U.S. Equal Employment Opportunity Commission+1

In India, the appropriate route depends on whether the dispute concerns a public authority, a private employer, an insurer, or the handling of personal data. A claimant should verify the current statutory framework and limitation period before commencing proceedings.

10. Comparative analysis: India and the United States

11. Practical example

Consider a healthy 32-year-old applicant whose genetic test identifies a pathogenic BRCA1 variant. The applicant has no cancer diagnosis and meets all stated qualifications for a job.

The employer learns about the variant and rejects the applicant because it expects the applicant to develop cancer in the future.

Under United States law: This would raise a strong potential claim under GINA, assuming the employer and other statutory requirements are covered. Genetic information generally cannot be used to make employment decisions.

U.S. Equal Employment Opportunity Commission+1

Under Indian law: The applicant could investigate whether the information was obtained or disclosed unlawfully, whether the decision involved arbitrary or otherwise prohibited discrimination, and whether applicable employment, privacy, or data-protection provisions were violated. A constitutional challenge may be particularly relevant to state employment. However, there is no automatic Indian statutory claim identical to GINA for every private-employment decision.

Insurance variation: If an insurer denies health coverage based solely on the same variant, the analysis must focus on the governing insurance regulations, the policy, the insurer's reasons, and the legal status of any relevant judicial authority. The result cannot safely be predicted from the genetic result alone.

12. Conclusion

Cancer genomic discrimination protections seek to prevent sensitive hereditary information from becoming an unjustified basis for exclusion, surveillance, or denial of opportunities.

The principal legal conclusions are:

Genetic susceptibility is not equivalent to a cancer diagnosis.

In India, K.S. Puttaswamy provides a significant constitutional foundation for protecting genomic privacy and autonomy.

United India Insurance Co. Ltd. v. Jay Prakash Tayal is relevant to genetic-disorder exclusions in health insurance, but its subsequent procedural history must be considered.

In the United States, GINA supplies explicit protections in employment and health coverage, while leaving important insurance and existing-disease issues outside its scope.

Effective protection requires more than confidentiality: it also requires limits on discriminatory decision-making, appropriate consent and data handling, fair procedures, and accessible remedies.

The broader legal challenge is to ensure that genomic medicine can improve cancer prevention and treatment without converting a person's inherited biological risk into an unjustified legal or economic disadvantage.

This is a general educational analysis, not an opinion on a particular dispute. For an actual claim, the jurisdiction, policy wording, decision date, and precise facts should be checked against current law.